Boehringer Targets High Unmet Need With Spesolimab Filing
Could Be First EU Approved Drug For Generalized Pustular Psoriasis Flares
Executive Summary
Boehringer Ingelheim files spesolimab in the EU, where it is a forerunner in the race to fill the unmet need in generalized pustular psoriasis flares.